MoonLake's Third Consecutive Quarter Without Revenue Before the BLA Decision

MoonLake Immunotherapeutics (MLTX) reports first-quarter 2026 earnings before the market opens on Monday, May 11, with analysts forecasting a loss of $0.91 per share. The biotech's stock has struggled over the past year, and investors will scrutinize whether the company's lead drug candidate, sonelokimab, can deliver clinical progress that justifies its valuation. With regulatory milestones on the horizon and a sharply divided analyst community, this report could set the tone for the remainder of 2026.

Part 1: Earnings Preview

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company developing sonelokimab, a novel Nanobody therapy targeting inflammatory diseases including hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. The company has no commercial revenue and is focused entirely on advancing its pipeline through clinical trials and regulatory approvals.

MLTX will report Q1 2026 results before the market opens on Monday, May 11, with analysts expecting a loss of $0.91 per share on no revenue. The company most recently reported Q4 2025 results on February 25, posting a loss of $0.92 per share, which met analyst expectations. Compared to the same quarter last year (Q1 2025), when MLTX reported a loss of $0.63 per share, the current estimate of $0.91 represents a 44.44% increase in losses year-over-year, reflecting higher operating expenses as the company advances its clinical programs.

Three key themes define this earnings story:

1. Regulatory Pathway Clarity for Hidradenitis Suppurativa: Following a positive FDA Type B meeting in January 2026, the agency indicated MLTX may establish substantial evidence of effectiveness for sonelokimab in HS without additional clinical trials, paving the way for a BLA submission in the second half of 2026. Investors will watch for updates on regulatory timelines and any new guidance from the FDA.

2. Clinical Progress Across Multiple Indications: The company announced positive Phase 2 results in axial spondyloarthritis in February 2026, with over 80% of patients achieving ASAS40 response by Week 12. With over 3,000 patients planned across its VELA program and other trials, investors will look for enrollment updates, trial milestones, and any new efficacy or safety data that could differentiate sonelokimab from established competitors.

3. Cash Runway and Financing Needs: With cash representing a significant portion of market cap (net debt-to-equity of -28%) and no revenue, burn rate is critical. Analysts will focus on operating expenses, cash balance, and management's guidance on how long current resources can fund operations before additional financing is required.

Analyst commentary ahead of the release is mixed. Wolfe Research upgraded MLTX from "underperform" to "outperform" in March 2026, raising its price target from $12 to $24, citing confidence in the clinical pipeline. Rothschild & Co upgraded the stock from "neutral" to "buy" with a $40 target, while Clear Street maintained a "Buy" rating with a $70 target. However, Goldman Sachs downgraded MLTX from "neutral" to "sell" in January, and the company faces shareholder litigation alleging it misled investors about sonelokimab's efficacy after a pivotal Phase 3 trial missed its primary endpoint.

Part 2: Historical Earnings Performance

MoonLake Immunotherapeutics has shown an inconsistent earnings track record over the past four quarters, with two beats, one miss, and one in-line result. In Q1 2025 (March), MLTX reported a loss of $0.63 per share versus an estimate of $0.76, delivering a +17.11% surprise and beating expectations. The following quarter, Q2 2025 (June), saw a miss with a loss of $0.87 against an estimate of $0.73, a -19.18% surprise. The pattern continued in Q3 2025 (September) with another miss: a loss of $1.10 versus an estimate of $0.89, representing a -23.60% surprise. Most recently, in Q4 2025 (December), MLTX reported a loss of $0.92 per share, exactly matching the consensus estimate of $0.92 with no surprise.

The trend reveals widening losses through mid-2025, with Q3's $1.10 loss marking the worst quarterly result in this period, before moderating slightly in Q4. The company's ability to control operating expenses while advancing multiple clinical programs has been uneven, and the two consecutive misses in Q2 and Q3 suggest challenges in managing burn rate. With the Q1 2026 estimate of $0.91 essentially flat with Q4's actual result, analysts appear to expect stabilization in quarterly losses, though the year-over-year comparison shows a 44% increase from Q1 2025's $0.63 loss.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

MoonLake Immunotherapeutics typically reports earnings before the market opens, meaning Day 0 represents the first full trading session where investors react to results, and Day +1 captures follow-through momentum.

MLTX has exhibited moderate volatility around earnings, with an average absolute Day 0 move of 2.35% and an average Day 0 range of 5.88%. Day +1 shows slightly higher average movement at 3.00% with a range of 5.35%, suggesting initial reactions often extend into the following session. The most dramatic post-earnings action occurred in August 2024, when the stock fell 1.98% on Day 0 but then surged 6.94% on Day +1 with a 10.17% intraday range, indicating a delayed positive reaction. Conversely, May 2025 saw a 4.45% Day 0 gain followed by a 4.08% Day +1 decline, demonstrating how early enthusiasm can reverse. Recent reports have shown more muted reactions: the February 2026 report produced only a 0.11% Day 0 move and a 2.96% Day +1 decline, while November 2025 saw a 4.54% Day 0 gain followed by a 2.83% Day +1 pullback. Overall, investors should expect mid-single-digit percentage swings in either direction, with the potential for follow-through moves that either amplify or reverse the initial reaction.

Part 2.2: Options Market Expected Move

The options market is pricing in an expected move of 9.22% (±$1.57) for the May 15 expiration, which is significantly higher than MLTX's average historical Day 0 move of 2.35% and even exceeds the average Day +1 move of 3.00%. This elevated implied volatility of 83.33% suggests options traders are anticipating a more dramatic reaction to this earnings report than the stock has typically delivered, possibly reflecting heightened uncertainty around regulatory updates, clinical trial progress, or cash burn guidance.

Part 3: What Analysts Are Saying

Analysts are divided on MoonLake Immunotherapeutics, with a consensus rating of 4.11 (Buy) and an average price target of $29.83, implying 74.9% upside from the current price of $17.06. The analyst community includes 12 Strong Buys, 1 Moderate Buy, 4 Holds, and 2 Strong Sells, reflecting a wide range of opinions on the company's prospects. Price targets span an exceptionally broad range from a low of $9.50 to a high of $70.00, underscoring the uncertainty surrounding sonelokimab's commercial potential and regulatory path.

Sentiment has remained unchanged over the past month, with the distribution of ratings holding steady at 12 Strong Buys, 1 Moderate Buy, 4 Holds, and 2 Strong Sells. This stability suggests analysts are waiting for new catalysts—such as regulatory updates, clinical data, or financing announcements—before adjusting their views. The bullish camp, led by firms like Clear Street (with a $70 target) and Rothschild & Co ($40 target), sees significant value in sonelokimab's differentiated mechanism and potential across multiple inflammatory indications. The bearish minority, including Goldman Sachs, remains concerned about competitive pressures, an undifferentiated clinical profile, and the risk that the company will need to raise capital at unfavorable terms.

The consensus target of $29.83 sits well above the current price, but the wide dispersion of estimates—from $9.50 to $70.00—highlights the binary nature of MLTX's investment thesis. Bulls see a path to blockbuster status if regulatory approvals materialize and clinical differentiation is demonstrated; bears worry about execution risk, cash burn, and the possibility that sonelokimab fails to stand out in a crowded market.

Part 4: Technical Picture

MoonLake Immunotherapeutics enters earnings with a deteriorating technical picture. The Barchart Technical Opinion currently shows a 16% Sell signal, unchanged from last week but down sharply from a 24% Buy signal one month ago, indicating a significant shift in momentum over the past four weeks.

Timeframe Analysis:

• Short-term (50% Sell): Moderate sell signal indicates near-term momentum has turned negative
• Medium-term (Hold): Neutral reading suggests consolidation in the intermediate timeframe
• Long-term (Hold): Neutral signal reflects a lack of clear directional bias in the longer-term trend

Trend Characteristics: The trend is showing Minimum strength and is Weakening, suggesting the stock is losing upward momentum and may be vulnerable to further downside if earnings disappoint.

MLTX is trading at $17.06, below its 5-day moving average of $17.31, below its 20-day moving average of $17.35, and below its 50-day moving average of $17.43, indicating short-term weakness. However, the stock remains above its 10-day moving average of $16.93 and its 100-day moving average of $16.47, providing some near-term support. The most concerning technical level is the 200-day moving average at $23.83, which sits 39.7% above the current price, underscoring the stock's significant underperformance over the past year.

Key support appears near the $16.50 level, where the 100-day moving average resides, while resistance is clustered around $17.30–$17.45, where the 5-day, 20-day, and 50-day averages converge. The overall technical setup is cautionary heading into earnings: the stock is trading below most short-term moving averages, momentum indicators have weakened sharply over the past month, and the trend is losing strength. A positive earnings surprise or bullish guidance could spark a relief rally back toward the $18–$19 range, but a disappointment risks a test of the $16 support zone or lower. With the options market pricing in a 9% move and technical indicators flashing caution, investors should brace for volatility.